Mary Kate Morris
California Department of Public Health
29 Papers
73 Citations
Mary Kate Morris is an academic researcher from California Department of Public Health. The author has contributed to research in topics: Biology & Medicine. The author has an hindex of 10, co-authored 14 publications. Previous affiliations of Mary Kate Morris include California Health and Human Services Agency & Centers for Disease Control and Prevention.
Chat about Author
Papers
Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant.
Xianding Deng,Miguel Garcia-Knight,Mir M. Khalid,Venice Servellita,Candace Wang,Mary Kate Morris,Alicia Sotomayor-Gonzalez,Dustin R. Glasner,Kevin Reyes,Amelia S. Gliwa,Nikitha P. Reddy,Claudia Sanchez San Martin,Scot Federman,Jing Cheng,Joanna Balcerek,Jordan E. Taylor,Jessica Streithorst,Steve Miller,Bharath Sreekumar,Pei-Yi Chen,Ursula Schulze-Gahmen,Taha Y. Taha,Jennifer M. Hayashi,Camille R. Simoneau,G. Renuka Kumar,Sarah McMahon,Peter V. Lidsky,Yinghong Xiao,Peera Hemarajata,Nicole M. Green,Alex Espinosa,Chantha Kath,Monica Haw,John Bell,Jill K. Hacker,Carl L. Hanson,Debra A. Wadford,Carlos Anaya,Donna Ferguson,Phillip A. Frankino,Haridha Shivram,Liana F. Lareau,Stacia K. Wyman,Melanie Ott,Melanie Ott,Raul Andino,Charles Y. Chiu +46 more
TL;DR: In this article, the authors identified an emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant by viral whole-genome sequencing of 2,172 nasal/nasopharyngeal swab samples from 44 counties in California, a state in the western United States.
525
Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination
Rahul K. Suryawanshi,Irene P. Chen,Tongcui Ma,Abdullah Muhammad Syed,N. Brazer,P. Saldhi,Camille R. Simoneau,Alison Ciling,Mir M. Khalid,Bharath K. Sreekumar,Pei-Hung Chen,G. Renuka Kumar,Mauricio Montano,Ronne Gascon,Chia-Lin Tsou,Miguel Garcia-Knight,Alicia Sotomayor-Gonzalez,Venice Servellita,Amelia S. Gliwa,Jenny Nguyen,I. Silva,B. Milbes,Noah Kojima,Victoria A. Hess,M. Shacreaw,Lauren Lopez,Matthew Brobeck,Fred E. Turner,Frank Soveg,Ashley F. George,Xiaohui Fang,Mazharul I. Maishan,Michael A. Matthay,Mary Kate Morris,Debra A. Wadford,Carly Hanson,Warner C. Greene,Raul Andino,Lee Spraggon,Nadia R. Roan,Charles Y. Chiu,Jennifer A. Doudna,Melanie Ott +42 more
TL;DR: This article showed that Omicron infection enhances pre-existing immunity elicited by vaccines but, on its own, may not confer broad protection against non-Omicron variants in unvaccinated individuals.
A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates
Payton A. Weidenbacher,Mrinmoy Sanyal,Natalia Friedland,Shaogeng Tang,Prabhu S. Arunachalam,Mengyun Hu,Ozan S. Kumru,Mary Kate Morris,Jane Fontenot,Lisa Shirreff,J. Do,Ya-Chen Cheng,Gayathri Vasudevan,Mark B. Feinberg,Francois Villinger,Carly Hanson,Sangeeta B. Joshi,David B. Volkin,Bali Pulendran,Peter S. Kim +19 more
TL;DR: DCFHP-alum as discussed by the authors is a protein-nanoparticle vaccine candidate that, when formulated with aluminum hydroxide as the sole adjuvant, elicits potent and durable neutralizing antisera in non-human primates against known VOCs including Omicron BQ.
A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants
Chang Yi Wang,Kao-Pin Hwang,Hui-Kai Kuo,Wen-Jiun Peng,Yea-Huei Shen,Ben Kuo,Juin-Hua Huang,Hope Liu,YuenFern Ho,Feng Lin,Shuang Ding,Zhi Liu,Huang-Ting Wu,Ching Tai Huang,Yuarn Jang Lee,Ming-Che Liu,Yi-Ching Yang,Po-Liang Lu,Hung Chin Tsai,Chen-Hsiang Lee,Zhi-Yuan Shi,Chun Eng Liu,Chun-Hsing Liao,C. Y. Chang,H. Cheng,Fu Der Wang,Kuo-Liang Hou,Jennifer W. Cheng,Min-Sheng Wang,Ya-Ting Yang,Han-Chen Chiu,Mingjuan Jiang,Hao Yu Shih,H. Shen,Po-Yen Chang,Yulu Lan,Chi-Tian Chen,Yi-Ling Lin,Jiangli Liang,Chun-Che Liao,Yu Chi Chou,Mary Kate Morris,Carl L. Hanson,Farshad Guirakhoo,Michael Hellerstein,Hui Jing Yu,Chwan-Chuen King,Tracy Kemp,D. Gray Heppner,Thomas P. Monath +49 more
TL;DR: The most striking findings were long-lasting virus-neutralizing antibodies and broad T cell immunity against SARS-CoV-2 variants of concern (VoCs), including Delta and Omicron, and a strong booster-recalled memory immunity with high cross-reactive neutralizing titers against the Delta and omicron VoCs.
50
Characterization of gp120 hydrolysis by IgA antibodies from humans without HIV infection.
Stephanie Planque,Yukie Mitsuda,Hiroaki Taguchi,Maria Salas,Mary Kate Morris,Yasuhiro Nishiyama,Robert A. Kyle,Pablo C. Okhuysen,Miguel A. Escobar,Robert L. Hunter,Haynes W. Sheppard,Carl V. Hanson,Sudhir Paul +12 more
TL;DR: The existence of catalytic IgAs to gp120 in uninfected humans suggests their role in resistance to HIV, and the neutralizing activity was specifically inhibited by an electrophilic inhibitor of the catalytic activity.
37